

Clonal Hematopoiesis in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy

Supplemental Material

Supplemental Figures

Supplemental Figure 1. Clonal Hematopoiesis Characteristics in CAR T-cell Cohort	1
Supplemental Figure 2. Cytokine Release Syndrome in CAR T-cell Cohort	2
Supplemental Figure 3. Relapse Free and Overall Survival in Cohort Stratified by Age Greater or Less than 60 Years Old	3

Supplemental Tables

Supplemental Table 1. Genes Sequenced for Determination of Clonal Hematopoiesis	4
Supplemental Table 2. Cohort Characteristics	5
Supplemental Table 3. Clonal Hematopoietic Mutations Identified in Cohort	6-9
Supplemental Table 4. Association between Clonal Hematopoiesis and Toxicity After CAR T-Cell Therapy	10

Supplemental Methods

11

Supplemental Figure 1. Clonal Hematopoiesis Characteristics in CAR T-cell Cohort.


A) The age distribution of patients in the cohort.

B) The maximum variant allele frequency identified in each patient with clonal hematopoiesis plotted for different age groups. The horizontal lines represent the medians in each age strata.

C) A co-mutation plot for all individuals with any clonal hematopoietic mutation identified. Each column is a patient and each row is a gene. The top two rows represent the total number of mutations (MaxNum) and maximum variant allele fraction (MAXVAF) identified in each patient with blue representing fewer and red representing more mutations.


D) Distribution of the number of mutations identified in patients in the cohort.

E) Distribution of the types of single nucleotide variants (SNVs) identified in the cohort.



Supplemental Figure 2. Cytokine Release Syndrome in CAR T-cell Cohort.

- A)** The distribution of cytokine release syndrome (CRS) grades per the American Society for Transplantation and Cellular Therapy (ASTCT) grading system across the cohort.
- B)** Maximum high sensitivity C-reactive protein (hsCRP) level in each patient stratified by maximum CRS grade recorded.
- C)** Maximum ferritin level in each patient stratified by maximum CRS grade recorded.
- D)** Maximum interleukin-6 (IL-6) level in each patient stratified by maximum CRS grade recorded.
- E)** Maximum ferritin, IL-6, and hsCRP levels for each patient stratified by absence (variant allele fraction [VAF] < 0.02) or presence (VAF > 0.02) of clonal hematopoiesis. Shown are median and interquartile range for (B)-(E).




Supplemental Figure 3. Relapse Free and Overall Survival in Cohort Stratified by Age Greater or Less than 60 Years Old.

A) Progression-free survival of patients younger than 60 years old with Non-Hodgkin lymphoma stratified by absence (red) or presence (orange) of clonal hematopoiesis with a variant allele fraction (VAF) greater than or equal to 0.02. A log-rank test was performed to compare survival curves.

B) Overall survival of patients younger than 60 years old with Non-Hodgkin lymphoma stratified by absence (red) or presence (orange) of clonal hematopoiesis with a variant allele fraction (VAF) greater than or equal to 0.02. A log-rank test was performed to compare survival curves.

C) Progression-free survival of patients older than 60 years old with Non-Hodgkin lymphoma stratified by absence (red) or presence (orange) of clonal hematopoiesis with a variant allele fraction (VAF) greater than or equal to 0.02. A log-rank test was performed to compare survival curves.

D) Overall survival of patients older than 60 years old with Non-Hodgkin lymphoma stratified by absence (red) or presence (orange) of clonal hematopoiesis with a variant allele fraction (VAF) greater than or equal to 0.02. A log-rank test was performed to compare survival curves.



Supplemental Table 1. Genes Sequenced for Determination of Clonal Hematopoiesis.

ASXL1	CSNK1A5	IDH2	PIGA	SRSF2
ATM	CSNK1A6	IKZF1	PIGT	STAG1
ATRX	CSNK1A7	JAK2	PPM1D	STAG2
B2M	CSNK1A8	JAK3	PRPF40B	STAT3
BCOR	CSNK1A9	KIT	PRPF8	STAT5B
BCORL1	CTCF	KRAS	PTEN	TERC
BRAF	CUX1	LUC7L2	PTPN11	TERT
BRCC3	DDX41	MIR142	RAD21	TET2
CALR	DNMT3A	MPL	RIT1	TP53
CBL	EP300	MRE11A	RPL11	U2AF1
CBLB	ETNK1	MYC	RPS7	U2AF2
CEBPA	ETV6	MYD88	RUNX1	VPS45
CREBBP	EZH2	MYH9	SETBP1	WT1
CSF1R	FANCL	NF1	SETD2	YLPM1
CSF3R	FLT3	NOTCH1	SF1	ZBTB33
CSNK1A1	FP SNP	NOTCH2	SF3A1	ZNF318
CSNK1A10	GATA1	NPM1	SF3B1	ZRSR2
CSNK1A11	GATA2	NRAS	SH2B3	
CSNK1A2	GNAS	PDS5B	SMC1A	
CSNK1A3	GNB1	PHF6	SMC3	
CSNK1A4	IDH1	PHIP	SRCAP	

Supplemental Table 2. Cohort Characteristics

Total Patients and CAR T-Cell Treatment (n)	154
Non-Hodgkin Lymphoma	144
Multiple Myeloma	10
Age (median, range)	63 (24-83)
Gender (n,%)	
Male	91 (59)
Female	63 (41)
Best Overall Response (n,%)	
Complete Remission	100 (65)
Partial Remission	32 (21)
Stable Disease	5 (3)
Progressive Disease	17 (11)
Prior Lines of Treatment (n,%)	
1-2	71 (46)
3-5	67 (44)
6-10	16 (10)
Prior Stem Cell Transplant (n,%)	
Autologous	41 (27)
Allogeneic	5 (3)
CRS Grade (n,%)	
0	22 (14)
1-2	114 (74)
3-4	16 (10)
5	2 (1)
Treatment for CRS (n,%)	
Tocilizumab	83 (54)
Steroids	59 (38)

Supplemental Table 3. Clonal Hematopoietic Mutations Identified in Cohort (continued).

chrom	pos_start	pos_end	ref	var	gene	cdna	aa	result	reads1	reads2	var_freq
4	106190860	106190860	C	T	TET2	c.C4138T	p.H1380Y	nonsynonymous SNV	808	170	0.1738
4	106180774	106180774	A	T	TET2	c.3804-2A>T		splicing	737	13	0.0173
4	106156651	106156651	-	TT	TET2	c.1552_1553insTT	p.I518fs	frameshift insertion	747	341	0.3131
4	106197002	106197002	G	-	TET2	c.5335delG	p.A1779fs	frameshift deletion	447	12	0.0261
4	106157620	106157620	G	-	TET2	c.2521delG	p.V841fs	frameshift deletion	991	78	0.073
4	106156025	106156025	-	A	TET2	c.927dupA	p.A309fs	frameshift insertion	1053	130	0.1099
4	106164769	106164769	G	A	TET2	c.G3637A	p.V1213M	nonsynonymous SNV	1076	7	0.0065
4	106155938	106155938	-	T	TET2	c.840dupT	p.S280fs	frameshift insertion	1489	14	0.0093
4	106164794	106164794	G	A	TET2	c.G3662A	p.C1221Y	nonsynonymous SNV	1186	70	0.0557
4	106194066	106194066	C	T	TET2	c.C4528T	p.Q1510X	stopgain	652	93	0.1248
4	106197208	106197208	G	A	TET2	c.G5541A	p.W1847X	stopgain	718	519	0.4196
4	106197244	106197244	T	-	TET2	c.5577delT	p.I1859fs	frameshift deletion	1260	9	0.0071
4	106157139	106157139	A	-	TET2	c.2040delA	p.R680fs	frameshift deletion	611	44	0.0672
4	106190795	106190795	G	C	TET2	c.G4073C	p.C1358S	nonsynonymous SNV	781	6	0.0076
4	106197366	106197366	T	C	TET2	c.T5699C	p.V1900A	nonsynonymous SNV	1446	22	0.015
4	106156932	106156932	G	-	TET2	c.1833delG	p.M611fs	frameshift deletion	851	10	0.0116
4	106197248	106197248	G	T	TET2	c.G5581T	p.G1861X	stopgain	1267	37	0.0284
4	106156747	106156747	C	T	TET2	c.C1648T	p.R550X	stopgain	1070	6	0.0056
4	106157371	106157371	C	T	TET2	c.C2272T	p.Q758X	stopgain	778	10	0.0127
4	106197013	106197017	O	-	TET2	c.5346_5350del	p.L1782fs	frameshift deletion	1152	12	0.0103
17	7578235	7578235	T	C	TP53	c.A614G	p.Y205C	nonsynonymous SNV	654	59	0.0827
17	7578457	7578457	C	T	TP53	c.G473A	p.R158H	nonsynonymous SNV	677	84	0.1104
17	7578191	7578191	A	G	TP53	c.T658C	p.Y220H	nonsynonymous SNV	427	102	0.1928
17	7577548	7577548	C	T	TP53	c.G733A	p.G245S	nonsynonymous SNV	1089	20	0.018
17	7578518	7578518	C	T	TP53	c.G412A	p.A138T	nonsynonymous SNV	830	5	0.006
17	7577539	7577539	G	A	TP53	c.C742T	p.R248W	nonsynonymous SNV	753	19	0.0246
17	7578406	7578406	C	T	TP53	c.G524A	p.R175H	nonsynonymous SNV	1356	150	0.0996
17	7577094	7577094	G	A	TP53	c.C844T	p.R282W	nonsynonymous SNV	917	5	0.0054
17	7577543	7577543	C	T	TP53	c.G738A	p.M246I	nonsynonymous SNV	950	8	0.0084
17	7577115	7577115	A	C	TP53	c.T823G	p.C275G	nonsynonymous SNV	1461	11	0.0075
17	7578403	7578403	C	A	TP53	c.G527T	p.C176F	nonsynonymous SNV	1672	13	0.0077
17	7577568	7577568	C	T	TP53	c.G713A	p.C238Y	nonsynonymous SNV	648	5	0.0077
17	7578475	7578475	G	C	TP53	c.C455G	p.P152R	nonsynonymous SNV	906	6	0.0066
17	7577094	7577094	G	A	TP53	c.C844T	p.R282W	nonsynonymous SNV	963	11	0.0113
17	7577120	7577120	C	T	TP53	c.G818A	p.R273H	nonsynonymous SNV	981	25	0.0249
17	7577138	7577138	C	G	TP53	c.G800C	p.R267P	nonsynonymous SNV	1190	59	0.0472
17	7578236	7578236	A	G	TP53	c.T613C	p.Y205H	nonsynonymous SNV	997	5	0.005
17	7577121	7577121	G	T	TP53	c.C817A	p.R273S	nonsynonymous SNV	1048	8	0.0076
17	7578191	7578191	A	T	TP53	c.T658A	p.Y220N	nonsynonymous SNV	738	8	0.0107
17	7578190	7578190	T	C	TP53	c.A659G	p.Y220C	nonsynonymous SNV	720	20	0.027
17	7577120	7577120	C	T	TP53	c.G818A	p.R273H	nonsynonymous SNV	1180	19	0.0158
17	7577532	7577532	G	A	TP53	c.C749T	p.P250L	nonsynonymous SNV	948	19	0.0196
17	7577022	7577022	G	A	TP53	c.C916T	p.R306X	stopgain	1063	14	0.013
17	7577559	7577559	G	A	TP53	c.C722T	p.S241F	nonsynonymous SNV	767	29	0.0364
17	7576865	7576865	A	T	TP53	c.T981A	p.Y327X	stopgain	676	95	0.1232
17	7577120	7577120	C	T	TP53	c.G818A	p.R273H	nonsynonymous SNV	985	27	0.0267
17	7577505	7577505	T	A	TP53	c.A776T	p.D259V	nonsynonymous SNV	643	6	0.0092
17	7578535	7578535	T	C	TP53	c.A395G	p.K132R	nonsynonymous SNV	1023	7	0.0068
17	7577124	7577124	C	A	TP53	c.G814T	p.V272L	nonsynonymous SNV	934	9	0.0095
17	7578550	7578550	G	A	TP53	c.C380T	p.S127F	nonsynonymous SNV	860	24	0.0271
17	7578442	7578442	T	C	TP53	c.A488G	p.Y163C	nonsynonymous SNV	1248	35	0.0273
17	7577574	7577574	T	C	TP53	c.A707G	p.Y236C	nonsynonymous SNV	689	54	0.0727
17	7577108	7577108	C	A	TP53	c.G830T	p.C277F	nonsynonymous SNV	909	154	0.1449
17	7578406	7578406	C	T	TP53	c.G524A	p.R175H	nonsynonymous SNV	1499	8	0.0053
17	7577098	7577100	O	-	TP53	c.838_840del	p.280_280del	nonframeshift deletion	1286	18	0.0138
17	7577580	7577580	T	C	TP53	c.A701G	p.Y234C	nonsynonymous SNV	925	8	0.0086
17	7577550	7577550	C	T	TP53	c.G731A	p.G244D	nonsynonymous SNV	796	12	0.0149
17	7577559	7577559	G	A	TP53	c.C722T	p.S241F	nonsynonymous SNV	1206	10	0.0082
17	7578442	7578442	T	C	TP53	c.A488G	p.Y163C	nonsynonymous SNV	1910	10	0.0052
17	7578503	7578503	C	T	TP53	c.G427A	p.V143M	nonsynonymous SNV	1749	14	0.0079
17	7578449	7578449	C	T	TP53	c.G481A	p.A161T	nonsynonymous SNV	1445	9	0.0062
17	7577114	7577114	C	T	TP53	c.G824A	p.C275Y	nonsynonymous SNV	1055	10	0.0094
17	7578191	7578191	A	G	TP53	c.T658C	p.Y220H	nonsynonymous SNV	721	13	0.0177
17	7574034	7574034	C	G	TP53	c.877-1G>C		splicing	727	17	0.0228
17	7578479	7578479	G	A	TP53	c.C451T	p.P151S	nonsynonymous SNV	1340	45	0.0325
17	7578190	7578190	T	C	TP53	c.A659G	p.Y220C	nonsynonymous SNV	674	60	0.0817
17	7579447	7579447	A	-	TP53	c.240delT	p.P80fs	frameshift deletion	1294	119	0.0842
17	7577570	7577570	C	T	TP53	c.G711A	p.M237I	nonsynonymous SNV	305	385	0.558
17	7577082	7577082	C	T	TP53	c.G856A	p.E286K	nonsynonymous SNV	1296	18	0.0137
17	7579717	7579717	G	C	TP53	c.C79G	p.P27A	nonsynonymous SNV	553	5	0.009
17	7578555	7578555	C	T	TP53	c.259-1G>A		splicing	625	299	0.3236
21	44514777	44514777	T	C	U2AF1L5	c.A470G	p.Q157R	nonsynonymous SNV	1047	11	0.0104
21	44514777	44514777	T	G	U2AF1L5	c.A470C	p.Q157P	nonsynonymous SNV	464	276	0.373
X	15841102	15841102	G	T	ZRSR2	c.G1186T	p.E396X	stopgain	585	6	0.0102

Supplemental Table 4. Association between Clonal Hematopoiesis and Toxicity After CAR T-Cell Therapy.

A) ASTCT cytokine release syndrome (CRS) grade stratified by age and CHIP status across entire cohort.

B) Clinical evidence of neurotoxicity stratified by age and CHIP status across in non-Hodgkin Lymphoma (NHL) patients.

A

	CH Status	Total Patients	ASTCT CRS Score		p-value*
			Grade < 2 # (%)	Grade ≥ 2 # (%)	
All Patients	VAF < 0.02	80	32 (40.0)	48 (60.0)	0.5
	VAF ≥ 0.02	74	25 (33.8)	49 (66.2)	
Age < 60	VAF < 0.02	40	21 (52.5)	19 (47.5)	0.032
	VAF ≥ 0.02	22	5 (22.7)	17 (77.3)	
Age ≥ 60	VAF < 0.02	40	11 (27.5)	29 (72.5)	0.37
	VAF ≥ 0.02	52	20 (38.5)	32 (61.5)	

* p-values were calculated using a Fisher's exact test

B

	CH Status	Total Patients	Neurotoxicity		p-value*
			No # (%)	Yes # (%)	
All NHL Patients	VAF < 0.02	76	43 (56.6)	33 (43.4)	0.066
	VAF > 0.02	67	27 (40.3)	40 (59.7)	
NHL Age < 60	VAF < 0.02	37	23 (62.2)	14 (37.8)	0.56
	VAF > 0.02	18	9 (50.0)	9 (50.0)	
NHL Age > 60	VAF < 0.02	39	20 (51.3)	19 (48.7)	0.20
	VAF > 0.02	49	18 (36.7)	31 (63.3)	

* p-values were calculated using a Fisher's exact test

Supplemental Methods

DNA Sequencing and Variant Calling

Following hybridization of sheared genomic DNA, we generated libraries tagged with duplex unique molecular identifiers using a custom bait set from Twist Bioscience (San Francisco, CA) targeting 101 genes recurrently mutated in CH (**Supplemental Table 1**). The bait set targeted regions of the genes previously shown to harbor recurrent, pathogenic variants (all regions targeted by the bait set will be made available upon request). Following UMI deduplication and alignment, we performed variant calling using Varscan version 2.2.3 and annotation using Annovar (April 2017 build). We classified variants as CH based on accepted criteria for pathogenicity and included variants with at least 5 supporting consensus reads in final analysis.^{16,17}

Statistical Methods

Exploratory endpoints included serum levels of high sensitivity C-reactive protein (hsCRP), ferritin, and interleukin-6 (IL-6) between groups with and without CH VAF > 0.02, stratified by age above or below 60. PFS and OS comparisons were performed using the log-rank test, comparisons of rates of best overall response, CRS, and frequency of CH between this and previously published cohorts were performed using Fisher's exact tests, and comparisons of continuous variables between groups (such as cytokine levels) were performed using Mann-Whitney U tests. Differences between groups were considered statistically significant at p-values < 0.05. All analyses were performed and the results plotted using R (v4.0.0) or PRISM (v9.0.0)